May 30, 2025, 08:12 AM by

May 30, 2025, 08:12 AM by

The appointment and ongoing science team expansion will help the company advance late-stage liver disease therapeutics

May 30, 2025, 01:00 AM by User Not Found

Bio-IT World | Pathos AI plans to continue investment in their AI foundation model for oncology; Stylus Medicine is emerging from stealth and advancing the company’s in vivo genetic medicines platform and pipeline of in vivo therapeutic programs; and more.

May 29, 2025, 01:00 AM by User Not Found

Bio-IT World | Illumina announced the launch of DRAGEN version 4.4 software; Lupus Research Alliance (LRA) announced the launch of the Lupus Nexus Foundational Analyses; and more.

May 28, 2025, 09:22 AM by

May 28, 2025, 09:22 AM by

Publication showcases the capabilities of Insilico's advanced generative AI platform and integrated workflow in facilitating the rapid development of ISM5939, further demonstrating the potential of AI in drug discovery. Unlike direct STING agonists, ISM5939 precisely modulates the STING pathway within tumor tissues by targeting ENPP1, thereby restoring local immune activation and enhancing anti-tumor immune responses. For the first time, ENPP1 inhibitors have been shown to overcome dual resistance to immune checkpoint inhibitors and chemotherapy, offering a new therapeutic hope for patients with refractory tumors. Since the start of 2025, this marks Insilico Medicine’s third AI-driven drug discovery study published in a Nature sub-journal. Immune checkpoint inhibitors have transformed cancer treatment, providing clinical benefits for a wide range of malignancies. However, only ~10-35% of patients on these treatments achieve a meaningful and durable response, underscoring the urgent need for innovative therapeutic strategies.

May 28, 2025, 09:22 AM by

AMP announced the release of a three-part series of papers on core bioinformatics capabilities for professionals in clinical molecular diagnostic labs.

May 28, 2025, 09:22 AM by

● Collaboration combines Nuclera’s eProtein Discovery System, which accelerates protein expression, purification and optimization, with Cytiva’s Biacore SPR system, which characterizes molecular interactions ● Collaboration allows researchers to progress rapidly from DNA to purified and characterized protein, to facilitate insights into drug-target interactions ● Showcased at Discovery on Target and PEGS Europe conferences, detailing the production and characterization of Bruton’s Tyrosine Kinase, which is implicated in B-cell malignancies

May 28, 2025, 09:22 AM by

Sapio Sciences, the science-aware™ lab informatics platform, today announced the promotion of Gordon McCall to Chief Operating Officer (COO). McCall has served as the company’s Chief Financial Officer (CFO) since 2022 and brings a proven track record of leadership, strategic execution, and operational acumen.

May 27, 2025, 08:24 AM by

This partnership will launch three new START research sites to bring early phase trials closer to patients in major U.S. communities.

May 27, 2025, 01:00 AM by User Not Found

Bio-IT World | The Access for All in ALS (ALL ALS) Consortium is spearheading an ambitious open science initiative that aims to transform how we understand and treat this devastating neurological disease. Led by Robert Bowser, Ph.D. of the Barrow Neurological Institute and James Berry, M.D. of Massachusetts General Hospital, the consortium is conducting two studies: ASSESS for people living with ALS and healthy controls and PREVENT for those with genetic risk factors but no symptoms.

May 22, 2025, 08:04 AM by

May 22, 2025, 08:04 AM by

Pythia Biosciences and Miraomics today announced their collaboration to develop Pythiomics—a rich, high-quality and harmonized single-cell omics database designed to accelerate discoveries and AI/ML development in drug research.

May 22, 2025, 01:00 AM by User Not Found

Bio-IT World | Singapore researchers have developed an innovative artificial intelligence platform that creates personalized “digital twins” of patients to optimize drug dosing on an individual basis. The CURATE.AI platform, developed by Dr. Dean Ho and his team at the National University of Singapore's Institute for Digital Medicine (WisDM), represents a significant advancement in precision medicine by dynamically adjusting treatment regimens based on real-time patient responses.

May 21, 2025, 08:57 AM by

4D Path, a company dedicated to personalizing cancer care through its unprecedented approach to predicting tumor response, recently convened its Scientific Advisory Board (SAB), bringing together an exceptional group of oncology, pathology, and translational research leaders, each deeply committed to advancing precision oncology and translating innovation into patient impact.

May 21, 2025, 08:57 AM by

Growth in dedicated sample stability facilities at Tramore (Ireland) site to meet demand for flexible, regulatory-compliant storage solutions

May 21, 2025, 01:00 AM by User Not Found

Bio-IT World | Genmab partnered with Genedata to address the challenges of capturing chromatography data. Their effort earned them a 2025 Innovative Practices Awards for their joint development of Chromatics, a new Genedata product developed to meet the needs of chromatography data. In their pursuit of differentiated therapeutic antibodies, Genmab found chromatography data a particularly unwieldy piece of the pipeline.

May 20, 2025, 08:41 AM by

May 20, 2025, 01:00 AM by User Not Found

Bio-IT World | DNA testing company 23andMe was purchased by Regeneron for $256 million. The deal is expected to close on July 1. The deal includes “substantially all assets” of 23and Me, but it will not include Lemonaid Health, a telehealth services provider that 23andMe plans to gradually close.

May 16, 2025, 08:36 AM by

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate strategic update.